Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors

摘要

Context: Natural strain variation and rapid resistance development makes development of broad spectrum hepatitis C virus (HCV) drugs very challenging and evaluation of inhibitor selectivity and resistance must account for differences in the catalytic properties of enzyme variants.